Dark

Check out our Level2View

CLVS
Clovis Oncology, Inc.
stock NASDAQ

Inactive

Dec 20, 2022

0.0812USD-5.581%(-0.0048)24,516,461

Pre-market

0.00USD-100.000%(-0.09)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsTrends

CLVS Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

CLVS Specific Mentions

As of Jul 10, 2025 12:36:29 AM EDT (<1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

192 days ago • u/YoursNothing • r/pennystocks • ckpt_the_best_opportunity_to_win_10x_your_money • C

Examples of Stocks Underperforming Post Approval
Clovis Oncology (CLVS):
After FDA approval of Rubraca for ovarian cancer, Clovis’ stock declined because of slower-than-expected sales and stiff competition from AstraZeneca’s Lynparza.
Investors were concerned about the drug’s ability to capture market share.
Amarin (AMRN):
After approval of Vascepa for cardiovascular risk reduction, Amarin’s stock struggled due to concerns about reimbursement and competitive challenges.
Sarepta Therapeutics (SRPT):
Sarepta’s stock initially fell after FDA approval of Exondys 51 for Duchenne muscular dystrophy because of skepticism over the limited clinical data supporting approval.
MannKind (MNKD):
MannKind’s Afrezza, an inhalable insulin, received FDA approval but the stock underperformed due to poor sales and challenges marketing the product.

sentiment -0.30

192 days ago • u/YoursNothing • r/pennystocks • ckpt_the_best_opportunity_to_win_10x_your_money • C

Examples of Stocks Underperforming Post Approval
Clovis Oncology (CLVS):
After FDA approval of Rubraca for ovarian cancer, Clovis’ stock declined because of slower-than-expected sales and stiff competition from AstraZeneca’s Lynparza.
Investors were concerned about the drug’s ability to capture market share.
Amarin (AMRN):
After approval of Vascepa for cardiovascular risk reduction, Amarin’s stock struggled due to concerns about reimbursement and competitive challenges.
Sarepta Therapeutics (SRPT):
Sarepta’s stock initially fell after FDA approval of Exondys 51 for Duchenne muscular dystrophy because of skepticism over the limited clinical data supporting approval.
MannKind (MNKD):
MannKind’s Afrezza, an inhalable insulin, received FDA approval but the stock underperformed due to poor sales and challenges marketing the product.

sentiment -0.30

Share